as the commonest cause of death in patients with a functioning renal transplant. . Data completeness for attainment of blood pressure targets remained variable between centres.
Introduction
This chapter includes independent analyses regarding renal transplant activity and survival data from the UK Transplant Registry, held by the Organ Donation and Transplantation Directorate (ODT) of NHS Blood and Transplant (NHSBT). The UK Renal Registry (UKRR) has performed additional analyses of renal transplant recipient follow-up data examining demographics, clinical and biochemical variables. NHSBT records all information regarding the episode of transplantation (donor and recipient details) and the UKRR holds additional information on key clinical and biochemical variables in renal transplant recipients. The co-operation between these two organisations results in a comprehensive database describing the clinical care delivered to renal transplant patients within the UK. This allows for the comparison of key quality measures between centres and provides insight into the processes involved in the care of such patients in the UK.
This chapter is divided into six sections: (1) transplant activity, waiting list and survival data; (2) transplant demographics; (3) clinical and laboratory outcomes; (4) analysis of prevalent patients by chronic kidney disease (CKD) stage; (5) estimated glomerular filtration rate (eGFR) slope analysis; and (6) cause of death in transplant recipients. Methodology, results and discussion of these analyses are provided in detail for all six sections separately.
The UKRR methodology has previously been described [1] . The UKRR collects quarterly clinical data via an electronic data extraction process from hospital based renal IT systems on all patients receiving renal replacement therapy. Throughout the chapter, the number preceding the centre name in each figure indicates the percentage of missing data for that centre for that variable.
In previous years, this chapter has used the Modification of Diet in Renal Disease (MDRD) study equation to estimate GFR from serum creatinine. In line with NICE recommendations and for consistency across the UKRR report, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation is used this year [2] . There is conflicting evidence as to whether either equation is superior in the transplant population although the EPI formula is felt to be more accurate at higher levels of eGFR [3] [4] [5] [6] . In light of this change, the authors advise caution in comparing eGFR results with previous published editions of this chapter. The NICE guidelines further recommend that laboratories using the MDRD equation to calculate eGFR consider changing their practice to using CKD-EPI.
Unless otherwise specified, prevalent transplant patients were defined as patients with a functioning renal transplant on 31 December 2016.
A list of the Renal Association recommended audit measures which were relevant to the transplant population in 2016 are given in appendix 1 of this chapter [7] . Several of the audit measures are not currently reported by the UKRR in the annual report; the reasons behind this are varied, but predominantly relate to a high proportion of incomplete data or that the relevant variable is not currently within the specified UKRR dataset.
Introduction NHSBT prospectively collects donor and recipient data at the time of transplantation. They also request that transplant centres provide an annual paper based data return on the status of the recipient including graft function. This enables ODT to generate comprehensive analyses of renal transplant activity and graft survival statistics, albeit on a financial year basis rather than a calendar year basis as is used in the UKRR report [9] .
NHSBT attributes a patient to the centre that performed the transplant operation irrespective of where the patient was cared for before or after the procedure and hence only reports on transplant centre performance.
Methods Results
During 2016, 3,328 kidney or kidney plus transplants were performed (table 3.1). The absolute number of living kidney donors showed a small decline in 2016, but still represented 30.6 % of all transplants performed. Deceased kidney-only transplants from both DBD and DCD increased 9% and 13% respectively. The number of kidney plus other organ transplants remained at a similar level, apart from a fall in kidney and pancreas transplant (−16%).
There were small differences in one-and five-year risk adjusted patient and graft survival rates amongst UK kidney transplant centres (table 3. 2). These graft survival rates include grafts with primary non-function, which are excluded from analysis by some registries.
Using data from the UKRR on prevalent renal transplant patients on 1 January 2016, the death rate during 2016 was 2.5 per 100 patient years (CI 2.3-2.7) when censored for return to dialysis, and 2.6 per 100 patient years (CI 2.5-2.8) without censoring for dialysis. These death rates were similar to those observed over the last five years and have not shown any impact from the increasing age or comorbidity of the transplanted cohort.
During 2016, 2.4% of prevalent transplant patients experienced graft failure and returned to dialysis (censored at death for patients who died with a functioning graft), which is slightly below the mean rate from 2010-2015 (2.5%) and a fall from the 2015 rate (2.7%).
Discussion
During 2016, there was a 5% increase in overall kidney transplant numbers due to increases in both types of deceased donor kidney transplants, partially offset by a further fall in the number of living kidney donors. Despite a small fall in 2015, there has been a steady increasing trend in total transplant numbers over the last decade. In the prevalent transplant population, the graft failure rate of 2.4% per annum and the patient death rate of 2.5 per 100 patient years has remained stable over recent years despite changes in the demographics of the transplanted cohort.
Transplant demographics

Introduction
Since 2008, all UK renal centres have established electronic linkage to the UKRR or Scottish Renal Registry, giving the UKRR complete coverage of individual patient level data across the UK.
The following sections should be interpreted in the context of centre-specific variations in repatriation policies; some transplant centres continued to follow up and report on all patients they transplanted, whereas others referred patients back to non-transplanting centres at some point post-transplant. Some transplant centres only referred back patients when their graft was failing. The time post-transplantation that a patient was referred back to their local centre varied between transplant centres, but the UKRR can detect duplicate patients (being reported from both transplant and referring centres) and in such situations care is usually attributed to the referring centre (see appendix B for allocation procedure). This process may result in some discrepancies in transplant numbers particularly in Oxford/Reading and Clwyd/Liverpool Royal. 
Methods
Cambridge renal centre (Addenbrooke's) has been unable to submit their 2015 and 2016 data. The centre was able to submit summary numbers of patients still on renal replacement therapy (RRT) at the end of 2016, by treatment modality, and incident numbers. Cambridge renal centre is therefore excluded from all centre level prevalent analyses. However their data have been included in the transplant rates calculation in England and UK, where only summary numbers are needed. For the calculation of transplant rates by Clinical Commissioning Groups (CCG) or Health Board/Social Care Areas (HB), where patient-level information are needed for age/sex standardisation, areas covered by Cambridge have been excluded. Based on prevalent transplant 2014 data, the percentage of patients resident in each CCG that was under the care of Cambridge renal centre at the end of 2014 was calculated. CCGs with .15% prevalent transplant patients seen in Cambridge were excluded from the analysis of the transplant prevalent rate by CCG in 2015 and 2016.
As Colchester did not have any transplant patients they were excluded from some of the analyses, although their dialysis patients were included in the relevant dialysis population denominators.
For the analysis of primary renal diagnosis (PRD) in transplant recipients, a few centres were excluded from some of the incidence years because of concerns relating to the reliability of PRD coding (with these centres submitting a high percentage of uncertain or missing aetiology codes).
Information on patient demographics (age, sex, ethnicity, PRD) for patients in a given renal centre was obtained from the UKRR patient registration data fields. Individual patients were assigned to the centre that returned data for them during 2016. The prevalence of transplant patients in areas covered by individual CCG or HB was estimated based on the postcode of the registered address for patients on RRT. Data on ethnic origin, supplied as Patient Administration System (PAS) codes, were retrieved from fields within renal centre IT systems. For the purpose of this analysis, patients were grouped into White, South Asian, Black, Other and Unknown categories. The details of ethnicity regrouping into the above categories are provided in appendix H: Coding www.renalreg.org/publications-reports/.
Results and Discussion
Prevalent transplant numbers across the UK are described in table 3.3. B QEH  93  97  85  92  97  99  93  95  Belfast  98  98  89  87  97  100  91  95  Bristol  96  96  86  87  96  100  96  96  Camb  95  95  88  89  98  100  96  95  Cardff  97  97  89  89  97  98  88  97  Covnt  90  90  88  87  99  100  95  96  Edin  95  95  83  85  99  100  87  93  Glasgw  93  93  93  93  97  100  91 Newc  95  95  81  86  99  100  93  95  Nottm  95  95  85  86  98  97  92  94  Oxford  95  95  88  89  96  99  95  93  Plymth  89  89  83  90  98  100  86  93  Ports  91  91  81  85  100  98  89  96  Sheff  96  96  84  91  99  100  95  98  All centres  94  94  86  88  98  99  92  95 The prevalence of renal transplant recipients in each CCG in England, Northern Ireland (Health and Social Care Trust Areas), Scotland (Health Boards) and Wales (Local Health Boards) and the proportion of prevalent patients according to modality in the renal centres across the UK are described in tables 3.4 and 3.5 respectively.
After standardisation for age and sex, unexplained variability was evident in the prevalence of renal Pyart/Wong/Sharples/Casula/Byrne Pyart/Wong/Sharples/Casula/Byrne transplant recipients, with some areas having higher than the predicted number of prevalent transplant patients per million population and others lower. This interpretation requires caution due to unadjusted underlying population differences and missing data. Variability in the prevalent transplant population may reflect differences in both wait-listing and transplantation rates, as well as differences in the outcomes of transplant recipients. As in previous years, a separate chapter of this report identifies continued significant inter-centre variation in access to transplant wait-listing and access to transplantation [10] . Centre differences in outcomes of transplantation are explored later in this chapter. A large national study (access to Transplant and Transplant Outcome Measures (ATTOM)) is currently investigating differences in access to and outcomes of renal transplantation [11] . The work has already identified significant age, ethnicity, socio-economic and geographic disparities in the utilisation of living kidney donor transplants in the UK [12] . The proportion of prevalent RRT patients with a transplant relative to the number on dialysis has gradually risen over the last decade.
Age and sex
The sex ratio amongst incident and prevalent kidney transplant patients has remained stable for at least the last six years (table 3.6, figure 3.1). The median age of incident transplant recipients increased during the same time period, which reflects changes to the renal replacement therapy population. This was mirrored by an increase in the median age of the prevalent population, which reflects the increase in age at which patients were transplanted, the increased access to transplantation for older recipients, as well as improved survival after kidney transplantation over the last ten years.
Primary renal diagnosis
The primary renal diagnosis of patients receiving a kidney transplant in the UK has remained relatively stable over the last five years (table 3.7).
Ethnicity
The ethnicity of those receiving a kidney transplant between 2011 and 2016 is shown in table 3.8. A comparison of the proportion of patients within each ethnic group receiving a transplant to those commencing dialysis from the same group was difficult because data on ethnicity were missing, or there was a high proportion with ethnicity classified as 'missing'. This is a particular issue in Scotland, where ethnicity reporting is not mandatory. There has been an increasing trend in the percentage of incident kidney recipients from non-White ethnic groups. This likely reflects the changing population of the UK and the different incidence of CKD in different ethnic groups. It may also reflect improved access to transplantation across these ethnic backgrounds through changes in the wait-listing of patients and changes in the national kidney allocation scheme.
Clinical and laboratory outcomes
Introduction There continued to be marked variation in the completeness of data (tables 3.9a, 3.9b) reported by each renal centre, particularly for blood pressure and parathyroid hormone, which limits the ability to perform more meaningful comparisons between centres, or determine the causes of inter-centre differences in outcomes. The 71 renal centres in the UK comprise 52 centres in England, five in Wales, five in Northern Ireland and nine in Scotland. Colchester was reported as having no transplanted patients and was therefore excluded.
Cambridge was unable to submit patient level data for 2015 and 2016. After exclusion of these centres, prevalent patient data from 69 renal centres across the UK were analysed. Middlbr  528  96  40  95  94  11  Newc  656  98  76  98  98  74  Norwch  389  96  97  96  96  27  Nottm  653  99  81  97  97  89  Oxford  1,161  99  65  99  98  42  Plymth  313  96  67  96  96  63  Ports  952  96  55  95  90  32  Prestn  592  98  74  97  96  47  Redng  417  99  77  98  76  57  Salford  505  99  80  99  99  0  Sheff  738  99  57  98  98  0  Shrew  129  95  86  93  93  12  Stevng  332  98  42  93  93  62  Sthend  91  99  34  98  96  8  Stoke  385  99  99  99  99  83  Sund  231  100  83  99  100  94  Truro  235  98  98  98  98  97  Wirral  101  89  37  84  84  51  Wolve  182  91  74  91  77  38  York  298  98  75  96  95  19 Outcomes in UK renal transplant recipients in 2016 For the one-year post-transplant analyses, in which patients were assigned to the centre that performed their transplant, all 23 transplant centres across the UK were included in the analysis.
Methods
Data for key laboratory variables were reported for all prevalent patients with valid data returns for a given renal centre (both transplanting and non-transplanting centres) and for one year post-transplant results for patients transplanted 2009-2015, with patients attributed to the transplant centre that performed the procedure.
Time since transplantation may have a significant effect on key biochemical and clinical variables and this was likely to be independent of a centre's clinical practices. Therefore, inter-centre comparison of data on prevalent transplant patients was open to bias. To minimise bias relating to fluctuations in biochemical and clinical parameters occurring in the initial post-transplant period, one year post-transplantation outcomes are also reported. It is presumed that patient selection policies and local clinical practices are more likely to be relevant in influencing 12 months post-transplant outcome, therefore comparison of outcomes between centres is more robust. However, even the 12 months post-transplant comparisons could be biased by differences in the repatriation of patients from the transplanting centre. In some centres repatriation of patients occurred at a fixed time post transplantation whilst in others it only occurred if the graft was failing or conversely if the graft function was stable.
Centres with ,10 patients or ,50% data completeness have been excluded from the figures. Scottish centres were also excluded from blood pressure analyses as data were not provided. Prevalent patient data Biochemical and clinical data for patients with a functioning transplant followed in either a transplanting or non-transplanting centre were included in the analyses. The cohort consisted of prevalent patients as on 31 December 2016. Patients were considered as having a functioning transplant if 'transplant' was listed as the last mode of RRT in the last quarter of 2016. Patients were assigned to the renal centre that sent the data to the UKRR but some patients will have received care in more than one centre. If data for the same transplant patient were received from both the transplant centre and non-transplant centre, care was usually allocated to the non-transplant centre (see appendix B). Patients with a functioning transplant of less than three months duration were excluded from analyses. For haemoglobin, estimated glomerular filtration rate (eGFR), corrected calcium, phosphate and blood pressure (BP), the latest value in quarter three or quarter four of 2016 was used.
Estimated glomerular filtration rate (eGFR)
For the purpose of eGFR calculation, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation formula was used, as advised by NICE recommendations [2] . Previous analyses have used the Modification of Diet in Renal Disease (MDRD) study equation therefore caution is needed in comparing with previous editions of this report. A wide variety of creatinine assays are in use in clinical biochemistry laboratories in the UK and it is not possible to ensure that all measurements of creatinine concentration collected by the UKRR are harmonised. Patients with valid serum creatinine results but no ethnicity data were classed as White for the purpose of the eGFR calculation.
One year post-transplant data
Patients who received a renal transplant between 1 January 2009 and 31 December 2015 were assigned according to the renal centre in which they were transplanted. In a small number of instances, the first documented evidence of transplantation in a patient's record was from a timeline entry of data returned from a non-transplant centre; patients were re-assigned to the nearest transplant centre in this scenario.
As this analysis is stratified by donor type, the donor type used in this analysis was obtained from NHSBT because the donor type reporting to the UKRR was poor from some renal centres.
Patients who died or experienced graft failure within 12 months of transplantation were excluded from the analyses. Patients with more than one transplant between 2009 and 2015 were included as separate episodes, provided that each of the retransplants functioned for at least a year.
The most recent laboratory or blood pressure result (for the relevant 4th/5th quarter) after renal transplantation was taken to represent one year post-transplant outcome. Patients with valid serum creatinine results but missing ethnicity data were assumed White for the purpose of the eGFR calculation.
Results and Discussion
Post-transplant eGFR in prevalent transplant patients When interpreting eGFR post-transplantation, it is important to note that the estimated GFR formulae only have a modest predictive performance in the transplant population [13] [14] , as summarised by centre in table 3.10. Some of the centre variability can be explained by differences in local repatriation policies for patients from transplanting centres back to referring centres; it is notable that both transplanting and non-transplanting centres feature at both ends of the scale in figure 3.3 . There continued to be marked variation between centres with 15 centres falling above and below the 95% CI. St Bartholomew's hospital and Manchester Royal infirmary both fell outside the upper 99.9% CI, suggesting a higher than expected proportion of patients with eGFR ,30 ml/min/1.73 m 2 .
eGFR in patients one year after transplantation Graft function at one year post-transplantation may predict subsequent long-term graft outcome [15] . Figures 3.5a, 3 .5b, and 3.5c show the median one-year post-transplant eGFR for patients transplanted between 2009-2015, by transplant centre and donor type. Patients who received kidney transplants from living kidney donors had the highest median eGFR at one year (57.2 ml/min/1.73 m 2 ), followed by donor after brainstem death (52.4 ml/min/1.73 m 2 ) and donor after circulatory death (48.4 ml/min/1.73 m 2 ). Figures 3.6a, 3.6b and 3 .6c show one-year posttransplant eGFR by donor type and year of transplantation. There was no significant trend in eGFR over the time period for patients who had either DBD, DCD or live kidney donor transplantation.
Haemoglobin in prevalent transplant patients
The Renal Association Anaemia guidelines recommend 'achieving a population distribution centred on a mean of 11g/dl with a range of 10-12g/dl' [16] (equivalent to 110 g/L, range 100-120 g/L). However, many transplant patients with good graft function have haemoglobin concentrations .120 g/L without using erythropoiesis stimulating agents, therefore it is inappropriate to audit performance using the higher limit.
A number of factors, including comorbidity, immunosuppressive medication, graft function, ACE inhibitor use, erythropoietin (EPO) use, intravenous or oral iron use, that affect centre-specific protocols for management of anaemia will affect haemoglobin concentrations in transplant patients. Most of these data are not collected by the UKRR and therefore haemoglobin attainment analyses have to be interpreted with caution. One centre (London St Bartholomew's) fell outside the upper 99.9% CI and two further centres (London Royal Free, London St Mary's Hammersmith) fell outside the upper 95% CI indicating a higher than predicted proportion of transplant patients not achieving the haemoglobin target. Six centres fell outside the lower 99.9% CI, indicating they performed better than expected with fewer than predicted patients having a haemoglobin ,100 g/L.
Blood pressure in prevalent transplant patients
The UK Renal Association (RA) guideline for the care of kidney transplant recipients recommends that 'Blood pressure should be <130/80 mmHg (or <125/75 mmHg if proteinuria)' [7] . This blood pressure (BP) target is Completeness of blood pressure data continued to be variable with some centres unable to report. Thirty-one centres returned data with .50% completeness and were included in the analysis. Despite restricting the analysis to only include centres with .50% completeness of data, there are other potential biases, especially for those with lower completeness (e.g. centres may be more likely to record blood pressure electronically for patients with poor BP control/other reasons for data to be missing systematically), therefore results should be interpreted with caution. poor outcomes, largely attributable to lack of specialist management of anaemia, acidosis, hyperphosphataemia and to inadequate advance preparation for dialysis. Transplant recipients on the other hand, are almost always followed up regularly in specialist transplant or renal clinics and it would be reasonable to expect patients with failing grafts to receive appropriate care and therefore have many of their modifiable risk factors addressed before complete graft failure and return to dialysis.
Methods
The transplant cohort consisted of prevalent transplant recipients as on 31 December 2016 and patients were classified according to the KDIGO staging criteria with the suffix of 'T' to represent Only patients on peritoneal dialysis were considered when examining differences in serum phosphate between transplant recipients and dialysis patients. For both the transplant and dialysis cohorts, the analysis used the most recent available value from the last two quarters of the 2016 laboratory data. Scottish centres were excluded from blood pressure, cholesterol and PTH analyses as corresponding data were not provided. 
Results and Discussion
Introduction
The gradient of deterioration in eGFR (slope) may predict patients likely to have early graft failure. The eGFR slope and its relationship to specific patient characteristics are presented here.
Methods
All UK patients aged 518 years receiving their first renal transplant between 1 January 2005 and 31 December 2014 were considered for inclusion. A minimum duration of 18 months graft function was required and three or more creatinine measurements from the second year of graft function onwards were used to plot eGFR slope. If a transplant failed but there were at least three creatinine measurements between one year post-transplant and graft failure, the patient was included but no creatinine Outcomes in UK renal transplant recipients in 2016 measurements after the quarter preceding the recorded date of transplant failure were analysed. Slopes were calculated using linear regression, assuming linearity, and the effect of age, ethnicity, sex, diabetes, donor type, year of transplant and current transplant status were analysed. P values were calculated using the Kruskal-Wallis test. eGFR was calculated using the CKD-EPI equation and results expressed as ml/min/ 1.73 m 2 /year.
Results and Discussion
The study cohort consisted of 17,353 patients. The median GFR slope was −0.7 ml/min/1.73 m 2 /year (table 3.12). The gradient was steeper for Black recipients (−1.26 ml/min/1.73 m 2 /year), in keeping with previously published data suggesting poorer outcomes for this group [17] .
There was no statistically significant difference in eGFR slope in recipients of deceased donor kidneys (−0.73 ml/ min/1.73 m /year). The slope was steeper in younger recipients, possibly reflecting differences in causes of graft failure including a higher risk of non-adherence as a contributory factor. An analysis of the causes of graft failure using UKRR data is currently awaiting publication and reflects the challenges of accurately coding the causes of graft failure. As might be expected, the steepest slope was in patients where the transplant subsequently failed. This analysis has assumed linearity of progression of fall in GFR and further work is ongoing to characterise the patterns of graft failure as well as the outcomes of patients with graft failure who transition on to dialysis. Introduction Differences in cause of death between dialysis and transplant patients may be expected due to selection for transplantation and use of immunosuppression. Chapter 5 includes a more detailed discussion on cause of death in dialysis patients.
Methods
The cause of death is sent by renal centres as an ERA-EDTA registry code. These have been grouped into the following categories: cardiac disease, cerebrovascular disease, infection, malignancy, treatment withdrawal, other and uncertain.
Some centres had high data returns to the UKRR regarding cause of death, whilst others returned no information. Provision of this information is not mandatory. Analysis of prevalent patients included all those aged over 18 years and receiving RRT on 1 January 2016. Table 3 .13 and figure 3 .11 show the differences in the cause of death between prevalent dialysis and transplant patients. Table 3 .14 shows the cause of death for prevalent transplant patients by age.
Results and Discussion
Death due to cardiovascular disease was less common in transplanted patients than in dialysis patients, perhaps reflecting the lower age of the transplanted patients. Cardiovascular screening undertaken during transplant work-up means transplant recipients are a pre-selected lower risk group of patients and over time, with good renal function, transplant recipients develop less vascular calcification. The leading cause of death amongst transplant patients was malignancy (23%) overtaking infection (22%) compared to last year. There has been a reduction over time in the proportion of deaths in transplant patients attributed to cardiovascular or cerebrovascular Cardiac disease  807  24  698  24  109  19  Cerebrovascular disease  159  5  129  5  30  5  Infection  696  20  570  20  126  22  Malignancy  351  10  218  8  133  23  Treatment withdrawal  565  17  544  19  21  4  Other  659  19  548  19  111  20  Uncertain  181  5  145  5  36  6  Total  3, Conflicts of interest: Dr E Sharples has received travel honoraria from Alexion pharmaceuticals.
